<p>在過去的 7 天裏，市場上漲了 3.4%，在過去一年中更是令人印象深刻地上漲了 30%，預計年收益將增長 16%。在如此強勁的市場條件下，識別財務狀況良好的股票對於希望抓住增長機會的投資者來説變得至關重要。儘管通常被視為過時的選擇，低價股在堅實的基本面支持下仍然具有潛力，提供了一種在大型公司中可能找不到的獨特價值與增長的結合。</p>
<h3>美國十大低價股</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>回報與風險</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.4011</td>
<td>$69.45M</td>
<td>✅ 3 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.19</td>
<td>$375.23M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>FinVolution Group (FINV)</td>
<td>$4.97</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.7079</td>
<td>$81.81M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$194.03M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.48</td>
<td>$369.14M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.14</td>
<td>$897.95M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.02</td>
<td>$52.12M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$328.13M</td>
<td>✅ 2 ⚠️ 1 查看分析 </td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國低價股篩選器中的 361 只股票的完整列表。</p>
<p>讓我們深入探討篩選器中的一些優質選擇。</p>
<h2>Ceragon Networks (CRNT)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Ceragon Networks Ltd. 為全球各地的蜂窩運營商和其他無線服務提供商提供無線傳輸解決方案，市值約為 2.0675 億美元。</p>
<p><strong>運營：</strong> 該公司作為全球創新者和領先的無線傳輸解決方案提供商，產生了 3.3873 億美元的收入。</p>
<p><strong>市值：</strong> $206.75M</p>
<p>Ceragon Networks Ltd. 正在應對無盈利的挑戰，2025 年最近的淨虧損為 209 萬美元，儘管它保持着強勁的現金狀況，短期資產超過其短期和長期負債。儘管目前缺乏盈利能力，該公司預計 2026 年的收入將顯著增長，介於 3.55 億至 3.85 億美元之間，並預計年收益將增長 90.75%。Ceragon 的管理團隊經驗豐富，平均任期為 4.9 年，表明在財務波動和行業競爭中領導層的穩定性。</p>
<ul>
<li>在我們的財務健康報告中更詳細地瞭解 Ceragon Networks 的潛力。</li>
<li>通過訪問我們的收益增長報告評估 Ceragon Networks 的前景。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/08f68317-5a21-4cf0-8836-1cd929c959c7/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/08f68317-5a21-4cf0-8836-1cd929c959c7/chart/debt-equity-history-analysis"/></p>
<p>截至 2026 年 4 月 CRNT 的債務與股本歷史及分析</p>
<h2>Caesarstone (CSTE)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Caesarstone Ltd. 設計、開發、製造和銷售各種品牌的工程石和瓷器產品，覆蓋美國、加拿大、拉丁美洲、澳大利亞、亞洲、歐洲、中東和非洲以及以色列，市值為 4702 萬美元。</p>
<p><strong>運營：</strong> 該公司從其建築產品部門產生了 3.9723 億美元的收入。</p>
<p><strong>市值：</strong> $47.02M</p>
<p>Caesarstone Ltd. 面臨財務挑戰，2025 年淨虧損為 1.3747 億美元，收入從 4.4322 億美元下降至 3.9723 億美元，反映出其無盈利狀態。儘管如此，該公司保持着強勁的現金狀況，短期資產為 2.531 億美元，超過短期負債 1.382 億美元和長期負債 1.211 億美元，表明短期內的財務穩定性。債務與股本比率在五年內從 7.3% 改善至 2.2%，但增加的波動性和有限的現金流仍然是潛在投資者在低價股中的擔憂。</p>
<ul>
<li>點擊探索我們在 Caesarstone 財務健康報告中的詳細發現。</li>
<li>在我們的歷史業績報告中探索 Caesarstone 的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/240901f4-ee73-418f-9d8d-4ecf64ca43f7/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/240901f4-ee73-418f-9d8d-4ecf64ca43f7/chart/debt-equity-history-analysis"/></p>
<p>截至 2026 年 4 月 CSTE 的債務與股本歷史及分析</p>
<h2>Protalix BioTherapeutics (PLX)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Protalix BioTherapeutics, Inc. 是一家生物製藥公司，專注於開發、生產和商業化重組治療蛋白，使用其 ProCellEx 植物細胞基礎的蛋白表達系統，市值為 1.8129 億美元。</p>
<p><strong>運營：</strong> 該公司從其生物技術（初創企業）部門產生了 5274 萬美元的收入。</p>
<p><strong>市值：</strong> $181.29M</p>
<p>Protalix BioTherapeutics, Inc. 最近獲得了歐洲委員會對 pegunigalsidase alfa 新劑量方案的批准，可能增強其在 Fabry 病治療中的市場地位。該批准使 Protalix 有資格獲得來自 Chiesi Global Rare Diseases 的 2500 萬美元的監管里程碑付款。儘管 2025 年報告淨虧損 660 萬美元，該公司預計 2026 年收入將增加，介於 7800 萬至 8300 萬美元之間，得益於預期的銷售增長和里程碑付款。Protalix 保持無債務，短期資產超過負債，表明在其無盈利狀態下的財務穩定性。</p>
<ul>
<li>在我們的詳細資產負債表健康報告中深入瞭解 Protalix BioTherapeutics 的具體情況。</li>
<li>在我們的增長報告中探索 Protalix BioTherapeutics 的分析師預測。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/65ba3298-13c3-4cf9-b3e1-38fa2f9a1459/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/65ba3298-13c3-4cf9-b3e1-38fa2f9a1459/chart/financial-position-analysis"/></p>
<p>截至 2026 年 4 月的 PLX 財務狀況分析</p>
<h2>下一步</h2>
<ul>
<li>點擊這裏，一鍵揭示我們美國便士股票篩選器中的 361 個隱藏寶石。</li>
<li>對其他可能性感興趣？今天最好的人工智能股票可能不在像 Nvidia 和 Microsoft 這樣的巨頭之中。通過這些 20 家專注於人工智能的小型公司，尋找下一個重大機會，這些公司在機器學習、自動化和數據智能方面的早期創新具有強大的增長潛力，可能為您的退休提供資金。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<h3><strong>新：</strong> 人工智能股票篩選器與警報</h3>
<p>我們的新人工智能股票篩選器每天掃描市場以發現機會。</p>
<p>• 分紅強勁的公司（收益率 3% 以上）</p>
<p>• 內部人士購買的被低估小型股</p>
<p>• 高增長的科技和人工智能公司</p>
<p>或者從 50 多個指標中構建您自己的篩選器。</p>
<p>立即免費探索</p>

Ceragon網絡

MAPS

Protalix生物治療

樂信集團

<p>市場在過去一週上漲了 3.4%，在過去一年中上漲了 30%，預計年收益將增長 16%。常常被忽視的低價股可以提供獨特的價值和增長機會。值得注意的低價股包括 WM Tech、樂信集團和 Ceragon Networks，儘管面臨一些財務挑戰，但顯示出顯著的收入增長潛力。Ceragon 預計年收入增長將達到 90.75%，而 Protalix 生物治療已獲得 2500 萬美元的里程碑付款，儘管目前虧損，但顯示出強勁的前景。投資者被鼓勵探索低價股市場中的這些機會</p>

<p>The market has climbed 3.4% in the last 7 days and an impressive 30% over the past year, with earnings projected to grow annually by 16%. In light of these robust market conditions, identifying stocks with strong financials becomes crucial for investors looking to capitalize on growth opportunities. Although often considered a relic, penny stocks still hold potential when backed by solid fundamentals, offering a unique blend of value and growth that might not be found in larger companies.</p>
<div class="lb-trans"><p>在過去的 7 天裏，市場上漲了 3.4%，在過去一年中更是令人印象深刻地上漲了 30%，預計年收益將增長 16%。在如此強勁的市場條件下，識別財務狀況良好的股票對於希望抓住增長機會的投資者來説變得至關重要。儘管通常被視為過時的選擇，低價股在堅實的基本面支持下仍然具有潛力，提供了一種在大型公司中可能找不到的獨特價值與增長的結合。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美國十大低價股</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.4011</td>
<td>$69.45M</td>
<td>✅ 3 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.19</td>
<td>$375.23M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>FinVolution Group (FINV)</td>
<td>$4.97</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.7079</td>
<td>$81.81M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$194.03M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.48</td>
<td>$369.14M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.14</td>
<td>$897.95M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.02</td>
<td>$52.12M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$328.13M</td>
<td>✅ 2 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>回報與風險</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.4011</td>
<td>$69.45M</td>
<td>✅ 3 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.19</td>
<td>$375.23M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>FinVolution Group (FINV)</td>
<td>$4.97</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.7079</td>
<td>$81.81M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$194.03M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.48</td>
<td>$369.14M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.14</td>
<td>$897.95M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.02</td>
<td>$52.12M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$328.13M</td>
<td>✅ 2 ⚠️ 1 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 361 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國低價股篩選器中的 361 只股票的完整列表。</p>
</div><p>Let's dive into some prime choices out of the screener.</p>
<div class="lb-trans"><p>讓我們深入探討篩選器中的一些優質選擇。</p>
</div><h2>Ceragon Networks (CRNT)</h2>
<div class="lb-trans"><h2>Ceragon Networks (CRNT)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Ceragon Networks Ltd. offers wireless transport solutions for cellular operators and other wireless service providers across various global regions, with a market cap of approximately $206.75 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Ceragon Networks Ltd. 為全球各地的蜂窩運營商和其他無線服務提供商提供無線傳輸解決方案，市值約為 2.0675 億美元。</p>
</div><p><strong>Operations:</strong> The company generated $338.73 million in revenue from its role as a global innovator and leading solutions provider of wireless transport.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司作為全球創新者和領先的無線傳輸解決方案提供商，產生了 3.3873 億美元的收入。</p>
</div><p><strong>Market Cap:</strong> $206.75M</p>
<div class="lb-trans"><p><strong>市值：</strong> $206.75M</p>
</div><p>Ceragon Networks Ltd. is navigating the challenges of being unprofitable, with a recent net loss of US$2.09 million for 2025, though it maintains a strong cash position with short-term assets exceeding both its short and long-term liabilities. Despite the current lack of profitability, the company forecasts significant revenue growth for 2026 between US$355 million and US$385 million and expects earnings to grow by 90.75% annually. Ceragon's management team is seasoned, with an average tenure of 4.9 years, suggesting stability in leadership amidst financial volatility and industry competition.</p>
<div class="lb-trans"><p>Ceragon Networks Ltd. 正在應對無盈利的挑戰，2025 年最近的淨虧損為 209 萬美元，儘管它保持着強勁的現金狀況，短期資產超過其短期和長期負債。儘管目前缺乏盈利能力，該公司預計 2026 年的收入將顯著增長，介於 3.55 億至 3.85 億美元之間，並預計年收益將增長 90.75%。Ceragon 的管理團隊經驗豐富，平均任期為 4.9 年，表明在財務波動和行業競爭中領導層的穩定性。</p>
</div><ul>
<li>Take a closer look at Ceragon Networks' potential here in our financial health report.</li>
<li>Evaluate Ceragon Networks' prospects by accessing our earnings growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的財務健康報告中更詳細地瞭解 Ceragon Networks 的潛力。</li>
<li>通過訪問我們的收益增長報告評估 Ceragon Networks 的前景。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/08f68317-5a21-4cf0-8836-1cd929c959c7/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/08f68317-5a21-4cf0-8836-1cd929c959c7/chart/debt-equity-history-analysis"/></p>
<p>CRNT Debt to Equity History and Analysis as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月 CRNT 的債務與股本歷史及分析</p>
</div><h2>Caesarstone (CSTE)</h2>
<div class="lb-trans"><h2>Caesarstone (CSTE)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Caesarstone Ltd. designs, develops, manufactures, and sells engineered stone and porcelain products under various brands across multiple regions including the United States, Canada, Latin America, Australia, Asia, Europe, the Middle East and Africa, and Israel with a market cap of $47.02 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Caesarstone Ltd. 設計、開發、製造和銷售各種品牌的工程石和瓷器產品，覆蓋美國、加拿大、拉丁美洲、澳大利亞、亞洲、歐洲、中東和非洲以及以色列，市值為 4702 萬美元。</p>
</div><p><strong>Operations:</strong> The company generates $397.23 million in revenue from its building products segment.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司從其建築產品部門產生了 3.9723 億美元的收入。</p>
</div><p><strong>Market Cap:</strong> $47.02M</p>
<div class="lb-trans"><p><strong>市值：</strong> $47.02M</p>
</div><p>Caesarstone Ltd. faces financial challenges, with a net loss of US$137.47 million for 2025 and declining revenues from US$443.22 million to US$397.23 million year-over-year, reflecting its unprofitable status. Despite this, the company maintains a strong cash position with short-term assets of US$253.1 million exceeding both short-term liabilities of US$138.2 million and long-term liabilities of US$121.1 million, indicating financial stability in the short term. The debt to equity ratio has improved over five years from 7.3% to 2.2%, but increased volatility and limited cash runway remain concerns for potential investors in penny stocks.</p>
<div class="lb-trans"><p>Caesarstone Ltd. 面臨財務挑戰，2025 年淨虧損為 1.3747 億美元，收入從 4.4322 億美元下降至 3.9723 億美元，反映出其無盈利狀態。儘管如此，該公司保持着強勁的現金狀況，短期資產為 2.531 億美元，超過短期負債 1.382 億美元和長期負債 1.211 億美元，表明短期內的財務穩定性。債務與股本比率在五年內從 7.3% 改善至 2.2%，但增加的波動性和有限的現金流仍然是潛在投資者在低價股中的擔憂。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Caesarstone's financial health report.</li>
<li>Explore historical data to track Caesarstone's performance over time in our past results report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在 Caesarstone 財務健康報告中的詳細發現。</li>
<li>在我們的歷史業績報告中探索 Caesarstone 的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/240901f4-ee73-418f-9d8d-4ecf64ca43f7/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/240901f4-ee73-418f-9d8d-4ecf64ca43f7/chart/debt-equity-history-analysis"/></p>
<p>CSTE Debt to Equity History and Analysis as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月 CSTE 的債務與股本歷史及分析</p>
</div><h2>Protalix BioTherapeutics (PLX)</h2>
<div class="lb-trans"><h2>Protalix BioTherapeutics (PLX)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its ProCellEx plant cell-based protein expression system, with a market cap of $181.29 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Protalix BioTherapeutics, Inc. 是一家生物製藥公司，專注於開發、生產和商業化重組治療蛋白，使用其 ProCellEx 植物細胞基礎的蛋白表達系統，市值為 1.8129 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its Biotechnology (Startups) segment, amounting to $52.74 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司從其生物技術（初創企業）部門產生了 5274 萬美元的收入。</p>
</div><p><strong>Market Cap:</strong> $181.29M</p>
<div class="lb-trans"><p><strong>市值：</strong> $181.29M</p>
</div><p>Protalix BioTherapeutics, Inc. has recently secured European Commission approval for a new dosing regimen of pegunigalsidase alfa, potentially enhancing its market position in the treatment of Fabry disease. The approval entitles Protalix to a significant US$25 million regulatory milestone payment from Chiesi Global Rare Diseases. Despite reporting a net loss of US$6.6 million for 2025, the company forecasts increased revenues between US$78 million and US$83 million in 2026, buoyed by expected sales growth and milestone payments. Protalix remains debt-free with short-term assets exceeding liabilities, suggesting financial stability amid its unprofitable status.</p>
<div class="lb-trans"><p>Protalix BioTherapeutics, Inc. 最近獲得了歐洲委員會對 pegunigalsidase alfa 新劑量方案的批准，可能增強其在 Fabry 病治療中的市場地位。該批准使 Protalix 有資格獲得來自 Chiesi Global Rare Diseases 的 2500 萬美元的監管里程碑付款。儘管 2025 年報告淨虧損 660 萬美元，該公司預計 2026 年收入將增加，介於 7800 萬至 8300 萬美元之間，得益於預期的銷售增長和里程碑付款。Protalix 保持無債務，短期資產超過負債，表明在其無盈利狀態下的財務穩定性。</p>
</div><ul>
<li>Dive into the specifics of Protalix BioTherapeutics here with our thorough balance sheet health report.</li>
<li>Explore Protalix BioTherapeutics' analyst forecasts in our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的詳細資產負債表健康報告中深入瞭解 Protalix BioTherapeutics 的具體情況。</li>
<li>在我們的增長報告中探索 Protalix BioTherapeutics 的分析師預測。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/65ba3298-13c3-4cf9-b3e1-38fa2f9a1459/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/65ba3298-13c3-4cf9-b3e1-38fa2f9a1459/chart/financial-position-analysis"/></p>
<p>PLX Financial Position Analysis as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 PLX 財務狀況分析</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><ul>
<li>Reveal the 361 hidden gems among our US Penny Stocks screener with a single click here.</li>
<li>Interested In Other Possibilities? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏，一鍵揭示我們美國便士股票篩選器中的 361 個隱藏寶石。</li>
<li>對其他可能性感興趣？今天最好的人工智能股票可能不在像 Nvidia 和 Microsoft 這樣的巨頭之中。通過這些 20 家專注於人工智能的小型公司，尋找下一個重大機會，這些公司在機器學習、自動化和數據智能方面的早期創新具有強大的增長潛力，可能為您的退休提供資金。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新：</strong> 人工智能股票篩選器與警報</h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我們的新人工智能股票篩選器每天掃描市場以發現機會。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 分紅強勁的公司（收益率 3% 以上）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 內部人士購買的被低估小型股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增長的科技和人工智能公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或者從 50 多個指標中構建您自己的篩選器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免費探索</p>
</div>

2026 年 4 月有潛力的便士股